title: Antiviral therapy for hepatitis C virus infection, cryoglobulinemic glomerulonephritis and low-grade malignant lymphoma: A challenge?
authors.forename: R
authors.initials: R
authors.lastname: Ennaifer
authors.forename: M
authors.initials: M
authors.lastname: Sabbah
authors.forename: R
authors.initials: R
authors.lastname: Hefaiedh
authors.forename: H
authors.initials: H
authors.lastname: Romdhane
authors.forename: M
authors.initials: M
authors.lastname: Cheikh
authors.forename: N
authors.initials: N
authors.lastname: Belhadj
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D003449:Cryoglobulinemia / Q000150:complications / Q000188:drug therapy*; D015433:Glomerulonephritis, Membranous / Q000150:complications / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications; D008297:Male; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000150:complications
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b